ALX ONCOLOGY HOLDINGS INC
Income Statement
| Line Item | FY2018 |
|---|---|
| Revenue | $2.1M |
| Cost of Revenue | — |
| Gross Profit | — |
| Gross Margin | — |
| Operating Expenses | |
| Research & Development | $11.3M |
| SG&A Expense | $2.6M |
| Operating Income | $-13.7M |
| Operating Margin | -662.0% |
| Interest Expense | — |
| Pretax Income | $-13.7M |
| Income Tax Expense | $45.0K |
| Net Income | $-13.7M |
| Net Margin | -664.3% |
| EPS (Basic) | $-0.53 |
| EPS (Diluted) | $-0.53 |
| Shares Outstanding (Basic) | 33.0M |
| Shares Outstanding (Diluted) | 33.0M |
| Dividends Per Share | — |